Enjoy yourself- Texas is one fine place to be.

Tim

You're welcome Doc Steve!

Tim

On Nov 4, 3:39 pm, "Tim Dixon" <timgdi...@cox.net> wrote:

Dear Tim

Could You send some more infos:
clinical observation datas ?. How long and who is running clinical
observation?
I am not against :)) However I am carefull in this matter.
All over the world A LOTS of clinicans have a problem to determine CR
or adjust
apt occlusion. In prosthodontics: denture are far away from really
treatment deivice :))

so shortly what benefits could we have from botox ?
Cosmetics  is NOT THE MOST IMPORTANT part in dentistry however
patients thinks like that
I noticed dental offices whitch serve not any treatment but cosmetics
service :))

regards kris Polanowski DDS
www.stomapol.pl

Hello Dr. Polanowski,

I will provide below a few links to some relative documentation from our site www.tmdcourses.com.

Allergan just released their phase 3 migraine/botox studies which are positive.

****************************************************
In the two Phase III clinical trials, patients were randomly assigned to treatment with BOTOX® or placebo injections every 12 weeks. The primary analysis was performed at week 24 following 2 treatment cycles. The two major efficacy measures evaluated in the trials were change from baseline in the number of headache episodes and number of headache days occurring in the 28 day-period preceding the week 24 time point. In Allergan's discussions with the FDA concerning the design of the Phase III clinical trials, the Agency considered number of headache days the preferred efficacy measure for the potential indication.

In the first Phase III clinical trial, Allergan prospectively selected number of headache episodes as the primary endpoint for evaluation. Number of headache days was selected as the major secondary endpoint. Results from the first Phase III clinical trial indicated that although both the BOTOX® and placebo treatment groups showed a statistically significant improvement from baseline, there was no significant difference in the reduction of number of headache episodes between patients receiving BOTOX® and placebo.

However, the study showed a decrease in number of headache days, the FDA's preferred efficacy measure, that was significantly greater in patients receiving BOTOX® vs. patients receiving placebo (p=0.006). The decrease in number of migraine/probable migraine days was also found to be significantly greater in patients treated with BOTOX® vs. patients receiving placebo (p=0.002).

Based on the data from the first Phase III clinical trial, the primary endpoint for the second Phase III study was prospectively changed to number of headache days, with number of headache episodes changed to a secondary endpoint, before the data were unmasked. In the second Phase III study, the primary endpoint and key secondary endpoints showed statistically significant benefit of BOTOX® treatment over placebo injections. Specifically, patients treated with BOTOX® demonstrated a significantly greater decrease in both number of headache days (p<0.001) and number of headache episodes (p=0.003). Similar to the first Phase III trial, the second study also showed a decrease in number of migraine/probable migraine days that was significantly greater in patients treated with BOTOX® vs. placebo (p<0.001).

In both Phase III clinical trials, BOTOX® treatments were well tolerated in patients suffering from chronic migraine. Also, in both studies, quality of life was evaluated using the validated Headache Impact Test (HIT6). Importantly, patients receiving BOTOX® treatments scored statistically significantly higher improvement in quality of life vs. patients receiving placebo injections (p<0.001 in both studies).

****************
Botulinum Toxin Type A in the Treatment of Dental Conditions by Andrew Blumenfeld, MD
This article appeared in the June 2007 Issue of Inside Dentistry and is in PDF format.
http://www.tmdcourses.com/pdf/botox-dental-conditions.pdf
****************
EMG analysis of effect {PowerPoint}
http://www.tmdcourses.com/docs/emg.ppt
****************
Published articles by Andrew Blumenfeld, M.D.
These documents are all in Adobe PDF Format.
     Botulinum Toxin Type A as an Effective Prophylactic Treatment in Primary Headache Disorders
     http://www.tmdcourses.com/docs/Blumenfeld%20271%20Patients.pdf
   
     Procedures for Administering Botulinum Toxin Type A for Migraine and Tension Type Headache
     http://www.tmdcourses.com/docs/Blumenfeld%20Methods.pdf
   
     Botulinum Toxin Type A for the Treatment of Headache {Pro}
     http://www.tmdcourses.com/docs/PRO&CON%20Headache%20Blumenfeld.pdf
   
     Botulinum Toxin Type A in the Treatment of Dental Conditions
     http://www.tmdcourses.com/pdf/botox-dental-conditions.pdf